MANKIND PHARMA LIMITEDMANKIND PHARMA LIMITEDMANKIND PHARMA LIMITED

MANKIND PHARMA LIMITED

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪1.20 T‬INR
52.80INR
‪19.13 B‬INR
‪103.34 B‬INR
‪64.54 M‬
Beta (1Y)
−0.05
Employees (FY)
‪19.54 K‬
Change (1Y)
‪+1.07 K‬ +5.80%
Revenue / Employee (1Y)
‪5.29 M‬INR
Net income / Employee (1Y)
‪978.96 K‬INR

About MANKIND PHARMA LTD


CEO
Sheetal Arora
Headquarters
New Delhi
Founded
1986
ISIN
INE634S01028
FIGI
BBG01G9WXG92
Mankind Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations across acute and chronic therapeutic areas. It offers products under the brands of Nurokind, Telmikind, Manforce, Unwanted, Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Prega News, Dydroboon, Cefakind, Monticope, and Caldikind. The company was founded by Ramesh Chand Juneja in 1986 and is headquartered in New Delhi, India.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
797MPL27
MPL-7.97%-16-11-27-PVT
Yield to maturity
Maturity date
Nov 16, 2027
799MPL26
MPL-7.99%-16-4-26-PVT
Yield to maturity
Maturity date
Apr 16, 2026
799MPL26A
MPL-7.99%-16-10-26-PVT
Yield to maturity
Maturity date
Oct 16, 2026

Explore more bonds 

Frequently Asked Questions


The current price of MANKIND is 2,910.40 INR — it has decreased by −3.03% in the past 24 hours. Watch MANKIND PHARMA LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BSE exchange MANKIND PHARMA LIMITED stocks are traded under the ticker MANKIND.
MANKIND stock has risen by 5.88% compared to the previous week, the month change is a 11.98% rise, over the last year MANKIND PHARMA LIMITED has showed a 53.09% increase.
We've gathered analysts' opinions on MANKIND PHARMA LIMITED future price: according to them, MANKIND price has a max estimate of 3,300.00 INR and a min estimate of 2,275.00 INR. Watch MANKIND chart and read a more detailed MANKIND PHARMA LIMITED stock forecast: see what analysts think of MANKIND PHARMA LIMITED and suggest that you do with its stocks.
MANKIND reached its all-time high on Dec 19, 2024 with the price of 2,920.05 INR, and its all-time low was 1,240.75 INR and was reached on May 22, 2023. View more price dynamics on MANKIND chart.
See other stocks reaching their highest and lowest prices.
MANKIND stock is 5.43% volatile and has beta coefficient of −0.05. Track MANKIND PHARMA LIMITED stock price on the chart and check out the list of the most volatile stocks — is MANKIND PHARMA LIMITED there?
Today MANKIND PHARMA LIMITED has the market capitalization of ‪1.17 T‬, it has increased by 12.78% over the last week.
Yes, you can track MANKIND PHARMA LIMITED financials in yearly and quarterly reports right on TradingView.
MANKIND PHARMA LIMITED is going to release the next earnings report on Jan 29, 2025. Keep track of upcoming events with our Earnings Calendar.
MANKIND earnings for the last quarter are 16.30 INR per share, whereas the estimation was 14.71 INR resulting in a 10.78% surprise. The estimated earnings for the next quarter are 12.80 INR per share. See more details about MANKIND PHARMA LIMITED earnings.
MANKIND PHARMA LIMITED revenue for the last quarter amounts to ‪30.77 B‬ INR, despite the estimated figure of ‪30.41 B‬ INR. In the next quarter, revenue is expected to reach ‪33.92 B‬ INR.
MANKIND net income for the last quarter is ‪6.53 B‬ INR, while the quarter before that showed ‪5.36 B‬ INR of net income which accounts for 21.80% change. Track more MANKIND PHARMA LIMITED financial stats to get the full picture.
No, MANKIND doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has ‪19.54 K‬ employees. See our rating of the largest employees — is MANKIND PHARMA LIMITED on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MANKIND PHARMA LIMITED EBITDA is ‪27.29 B‬ INR, and current EBITDA margin is 24.98%. See more stats in MANKIND PHARMA LIMITED financial statements.
Like other stocks, MANKIND shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MANKIND PHARMA LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MANKIND PHARMA LIMITED technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MANKIND PHARMA LIMITED stock shows the strong buy signal. See more of MANKIND PHARMA LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.